Benevolent Platform™
A publicly listed biopharma AI company pairing a decade-built knowledge graph with drug discovery science.
At a glance
Starts at
Free
No paid plan found on the vendor's site, September 2026.
Free tier
Yes
Platforms
Web
Best for
Biopharma decision makers wanting AI-backed drug discovery support
Not for
Individuals outside biopharma or life sciences work
3.9 out of 5
Scored by a Toolio reviewer after real useOur verdict
BenevolentAI, listed on Euronext Amsterdam, combines science and technology teams around a proprietary knowledge graph and ontologies to support biopharma drug discovery, offered through its Qor function for decision makers and life science consultancies. Organizations working in biopharma get a partner built specifically around that domain's science and data. It's an enterprise-facing platform rather than a self-serve tool, and the site does not publish pricing details for prospective organizational clients.
✓What it does well
Cross-disciplinary AI teamsDedicated science and technology teams work together on applying AI to drug discovery.
Decade-built knowledge graphA knowledge graph and ontologies developed over a decade underpin its AI capabilities.
Support for decision makersQor gives biopharma executives and consultancies an always-on strategic resource.
✕Where it falls short
Enterprise-only accessAccess is built for biopharma organizations, without a self-serve option for individuals.
No published pricingThe site does not publish pricing details for prospective organizational clients.
Biopharma-specific scopeThe platform stays narrow in scope, covering biopharma and life sciences rather than general research.
Key features
Biopharma-focused AIAI and machine learning are applied specifically to drug discovery challenges.
Proprietary ontologiesProprietary ontologies and a knowledge graph support the platform's models.
Qor strategic toolQor functions as an always-on strategic resource for biopharma decision makers.
Consultancy supportIt extends support to life science consultancies as well as biopharma companies.